Description: Platinum-based cancer chemotherapy first appeared in the cancer treatment literature with the landmark discovery of the anticancer activity of cisplatin in a publication of Dr. Barnet Rosenberg. Since that time hundreds of new platinum-containing agents have been synthesized with the focus on reducing side effects while retaining the antitumor activity of the parent molecule from which carboplatin emerged as a significant new platinum-based drug with markedly less patient morbidity than cisplatin. Since that time the focus of platinum drug development has been on the critical clinical need to broaden the number of tumor types responding to this class of drug. Currently there are nearly 30 platinum-based drugs in clinical trials and their structural diversity continues to expand the ongoing trials. This book merges the multidisciplinary approach of anticancer drug research with contributions from synthetic chemists, molecular biologists, pharmacologists and oncologists.

Please Wait